NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/30/2020 13:30
Last Report Issued 01/20/2014 13:23

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 4366SP-POS
Patient ID 4366SP-POS
Chain 14000175
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 14000175

Received 01/20/2014 12:33

Sample ID 14000175-001
Matrix Serum or Plasma
Patient Name 4366SP-POS
Patient ID 4366SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
4366SP Teriflunomide (Therapeutic Drug Monitoring), Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Teriflunomide	50000	ng/mL	500	
Synonym(s): Aubagio®				
Teriflunomide is indicated for the treatment of patients with relapsing forms of multiple sclerosis. It takes approximately 3 months to reach steady-state concentrations.				
Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL.				
Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. THIS TEST IS NOT MEANT TO MONITOR THE ELIMINATION OF TERIFLUNOMIDE IN WOMEN OF CHILDBEARING POTENTIAL WHO DISCONTINUE TERIFLUNOMIDE. The drug carries a black box warning for hepatotoxicity and teratogenicity.				

Results for sample 14000175-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Sample ID 14000175-001
Matrix Serum or Plasma
Patient Name 4366SP-POS
Patient ID 4366SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.